Randomized, Placebo Controlled, Crossover Study in an Environmental Challenge Chamber to Assess Safety & Efficacy of Three Oral Doses of BI 671800 Versus Fluticasone Propionate and Montelukast in Sensitive Seasonal Allergic Rhinitis Patients Out of Season

2 capsules of BI 671800 ED 25 mg

2 capsules of BI 671800 ED placebo (bid in the morning and evening)

1 over-encapsulated montelukast placebo tablet (qd in the morning)

1 over-encapsulated montelukast placebo tablet (qd in the morning)

fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)

fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)

fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)

4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)

4 capsules of BI 671800 ED placebo (bid in the morning and evening)

4 capsules of BI 671800 ED placebo (bid in the morning and evening)

4 capsules of BI 671800 ED placebo (bid in the morning and evening)

2 capsules of BI 671800 ED 100 mg (bid in the morning and evening)

2 capsules of BI 671800 ED placebo (bid in the morning and evening)

1 over-encapsulated montelukast placebo tablet (qd in the morning)

1 over-encapsulated montelukast placebo tablet (qd in the morning)

1 over-encapsulated montelukast placebo tablet (qd in the morning)

1 over-encapsulated montelukast 10 mg tablet (qd in the morning)

fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)

fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)

Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 mcg per nostril)